Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PYGL | P06737 | 5/20 | 0.43 |
| ▸ | PYGM | P11217 | 5/20 | 0.43 |
| ▸ | DDB1 | Q16531 | 2/20 | 0.40 |
| ▸ | CRBN | Q96SW2 | 2/20 | 0.40 |
| ▸ | RIPK1 | Q13546 | 6/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.39 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.39 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.39 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.39 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2281716 | 1.00 | PYGL (0.43) | PYGLPYGMDDB1CRBNRIPK1 | |
| SCHEMBL2283000 | 0.86 | KIF11 (0.38) | PYGLPYGMDDB1CRBNRIPK1 | |
| SCHEMBL2279613 | 0.86 | KIF11 (0.38) | PYGLPYGMDDB1CRBNRIPK1 | |
| SCHEMBL17312604 | 0.84 | OPRM1 (0.35) | PYGLPYGMDDB1CRBNMAPT | |
| SCHEMBL17312602 | 0.84 | OPRM1 (0.35) | PYGLPYGMDDB1CRBNMAPT | |
| SCHEMBL17312416 | 0.83 | CMA1 (0.39) | PYGLPYGMDDB1CRBNRIPK1 | |
| SCHEMBL2284752 | 0.83 | RIPK1 (0.43) | PYGLPYGMDDB1CRBNRIPK1 | |
| SCHEMBL2283134 | 0.83 | RIPK1 (0.43) | PYGLPYGMDDB1CRBNRIPK1 | |
| SCHEMBL17312415 | 0.83 | CMA1 (0.39) | PYGLPYGMDDB1CRBNRIPK1 | |
| SCHEMBL2361799 | 0.83 | DDB1 (0.41) | DDB1CRBNRIPK1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3508484-A1 | HETEROCYCLIC AMIDES AS KINASE INHIBITORS | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2019-07-10 | — | — | EP | disclosed |
| US-9556152-B2 | Heterocyclic amides as kinase inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2017-01-31 | — | — | US | disclosed |
| US-20150353533-A1 | HETEROCYCLIC AMIDES AS KINASE INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2015-12-10 | — | — | US | disclosed |
| US-7994162-B2 | 2-alkoxy-3,4,5-trihydroxy-alkylamide-benzazepines, the preparation and use thereof, and compositions containing the same | SANOFI-AVENTIS (FR) | 2011-08-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150353533-A1 | HETEROCYCLIC AMIDES AS KINASE INHIBITORS | CNKSR1, ARAF, MAP3K3 | PYGL 1691/4885PYGM 2644/4885DDB1 2611/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.